191 related articles for article (PubMed ID: 32996396)
1. Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region.
Chinthammit C; Bhattacharjee S; Axon DR; Slack M; Bentley JP; Warholak TL; Wilson DL; Lo-Ciganic WH
J Manag Care Spec Pharm; 2020 Oct; 26(10):1309-1316. PubMed ID: 32996396
[TBL] [Abstract][Full Text] [Related]
2. Association of low-income subsidy, medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries.
Chinthammit C; Bhattacharjee S; Lo-Ciganic WH; Axon DR; Slack M; Bentley JP; Warholak TL
Res Social Adm Pharm; 2022 Apr; 18(4):2634-2642. PubMed ID: 34006485
[TBL] [Abstract][Full Text] [Related]
3. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
Jung K; McBean AM; Kim JA
J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
[TBL] [Abstract][Full Text] [Related]
4. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
5. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
[No Abstract] [Full Text] [Related]
6. Evaluation of an integrated adherence program aimed to increase Medicare Part D star rating measures.
Leslie RS; Tirado B; Patel BV; Rein PJ
J Manag Care Spec Pharm; 2014 Dec; 20(12):1193-203. PubMed ID: 25443513
[TBL] [Abstract][Full Text] [Related]
7. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
[TBL] [Abstract][Full Text] [Related]
9. A Multichannel Medication Adherence Intervention Influences Patient and Prescriber Behavior.
Leslie RS; Gilmer T; Natarajan L; Hovell M
J Manag Care Spec Pharm; 2016 May; 22(5):526-38. PubMed ID: 27123914
[TBL] [Abstract][Full Text] [Related]
10. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
11. Use of High-Risk Medications Among Older Adults Enrolled in Medicare Advantage Plans vs Traditional Medicare.
Figueroa JF; Dai D; Feyman Y; Garrido MM; Tsai TC; Orav EJ; Frakt AB
JAMA Netw Open; 2023 Jun; 6(6):e2320583. PubMed ID: 37368399
[TBL] [Abstract][Full Text] [Related]
12. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
[TBL] [Abstract][Full Text] [Related]
13. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
14. Medicare Part D: early findings on enrollment and choices for rural beneficiaries.
McBride TD; Terry TL; Mueller KJ
Rural Policy Brief; 2006 Apr; 10(8 (PB2006-8)):1-9. PubMed ID: 16685809
[TBL] [Abstract][Full Text] [Related]
15. Variability of COPD inhaler coverage in Medicare Part D.
Wormser B; Socal MP; Anderson G
Am J Manag Care; 2021 May; 27(5):187-193. PubMed ID: 34002960
[TBL] [Abstract][Full Text] [Related]
16. Drug plan design incentives among Medicare prescription drug plans.
Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
[TBL] [Abstract][Full Text] [Related]
17. How does drug treatment for diabetes compare between Medicare Advantage prescription drug plans (MAPDs) and stand-alone prescription drug plans (PDPs)?
Erten MZ; Stuart B; Davidoff AJ; Shoemaker JS; Bryant-Comstock L; Shenolikar R
Health Serv Res; 2013 Jun; 48(3):1057-75. PubMed ID: 23205568
[TBL] [Abstract][Full Text] [Related]
18. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use.
Almodovar AS; Axon DR; Coleman AM; Warholak T; Nahata MC
J Manag Care Spec Pharm; 2018 May; 24(5):416-422. PubMed ID: 29694292
[TBL] [Abstract][Full Text] [Related]
20. Receipt of high risk medications among elderly enrollees in Medicare Advantage plans.
Qato DM; Trivedi AN
J Gen Intern Med; 2013 Apr; 28(4):546-53. PubMed ID: 23129159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
